Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Jun;23(3):439-44.
doi: 10.3346/jkms.2008.23.3.439.

Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis

Ho-Jin Shin  1 , Joo Seop Chung, Je-Jung Lee, Sang Kyun Sohn, Young Jin Choi, Yeo-Kyeoung Kim, Deok-Hwan Yang, Hyeoung-Joon Kim, Jong Gwang Kim, Young Don Joo, Won Sik Lee, Chang-Hak Sohn, Eun Yup Lee, Goon Jae Cho
Affiliations
Clinical Trial

Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis

Ho-Jin Shin et al. J Korean Med Sci. 2008 Jun.

Abstract

The objective of the current study was to investigate the treatment outcomes for the use of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) chemotherapy in adult patients with hemophagocytic lymphohistiocytosis (HLH). Seventeen HLH patients older than 18 yr of age were treated with CHOP chemotherapy. A response evaluation was conducted for every two cycles of chemotherapy. With CHOP chemotherapy, complete response was achieved for 7/17 patients (41.2%), a partial response for 3/17 patients (17.6%), and the overall response rate was 58.8%. The median response duration (RD) was not reached and the 2-yr RD rate was 68.6%, with a median follow-up of 100 weeks. Median overall survival (OS) was 18 weeks (95% CI, 6-30 weeks) and the 2-yr OS rate was 43.9%. Reported grade 3 or 4 non-hematological toxicities were increased serum liver enzyme levels and stomatitis. Grade 3 or 4 hematological toxicities were leukopenia (50.8%), anemia (20%), and thrombocytopenia (33.9%). Neutropenic fever was observed in 21.6% of patients (14/65 cycles), and most of the cases were resolved with supportive care including treatment with broad-spectrum antibiotics. CHOP chemotherapy seems to be effective in adult HLH patients and the toxicities are manageable.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Two-year response duration rate 68.6% (A) and overall survival rate 43.9% (B) for adult patients with hemophagocytic lymphohistiocytosis.
Fig. 2
Fig. 2
Serial serum LDH level. (A) HLH patients who showed CR after CHOP chemotherapy. (B) HLH patients who showed PR or NR after CHOP chemotherapy.
See this image and copyright information in PMC

References

    1. Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol. 2004;124:4–14. - PubMed
    1. Miyahara M, Sano M, Shibata K, Matsuzaki M, Ibaraki K, Shimamoto Y, Tokunaga O. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol. 2000;79:378–388. - PubMed
    1. Imashuku S, Hibi S, Ohara T, Iwai A, Sako M, Kato M, Arakawa H, Sotomatsu M, Kataoka S, Asami K, Hasegawa D, Kosaka Y, Sano K, Igarashi N, Maruhashi K, Ichimi R, Kawasaki H, Maeda N, Tanizawa A, Arai K, Abe T, Hisakawa H, Miyashita H, Henter JI. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999;93:1869–1874. - PubMed
    1. Gencik A, Signer E, Muller H. Genetic analysis of familial erythrophagocytic lymphohistiocytosis. Eur J Pediatr. 1984;142:248–252. - PubMed
    1. Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study group of the Histiocyte Society. Med Pediatr Oncol. 1997;28:342–347. - PubMed

Publication types

MeSH terms

Supplementary concepts